openpr.com
Cure8 news brief
Why This Matters
The release reports many active and planned clinical trials for Crohn’s disease that could lead to new treatment options in coming years. It names specific late-stage and combination studies relevant to patients with moderate-to-severe disease.
Who Should Pay Attention
Adult patients with moderate-to-severe Crohn's disease, patients on biologics, clinicians, and researchers following drug development
Study Snapshot
Story typePress release
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
The item is a press release promoting a pipeline report rather than a primary research paper. It names specific drug development activities: Sanofi’s Phase 3 induction study of duvakitug, AbbVie’s planned pediatric Phase 3 risankizumab study, Eli Lilly’s Phase 2 study testing an FXR agonist (LY4395089) with mirikizumab, and Merck’s study of tulisokibart.
The release emphasizes the size of the pipeline (90+ companies/drugs) and describes the report’s scope (clinical and nonclinical-stage products, product types, routes, and inactive programs).
Keep In Mind
Source is a press release promoting a paid market report (DelveInsight) and summarizes trial announcements; it does not provide study results or independent analysis. Verify details in trial registries or primary publications before drawing clinical conclusions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
PublisheropenPR
AuthorsABNewswire
Indexed viaGoogle News
Source typeWeb article
PublishedSep 25, 2026, 1:29 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast ...
A market analysis listing late‑stage investigational therapies and growing use of IL‑23 and S1P pathway drugs signals potential new treatment options and changing prescribing patterns that may affect access, choice, and...
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.